Novo Nordisk's September Test: A Bruised Stock Seeks Answers in London
Published on 09/07/2026 at 00:00 | Editorial boerse-global.de
The numbers tell a sobering story. Novo Nordisk's shares closed Friday at €40.09, down 1.8% on the day and 27% below January's high of €54.86. Year-to-date losses stand at 8.9%, stretching to 17% over twelve months. The stock now trades comfortably beneath its 50-day moving average of €41.64 — a technical signal that the near-term trend has yet to turn.
Yet the weekly picture offers a flicker of relief: a 1.8% gain over five sessions and 3.5% over the month. Whether that counts as a genuine floor or merely a pause before further declines is the question hanging over the Danish pharmaceutical giant as it approaches its Capital Markets Day on September 21 in London.
A Pipeline Setback That Won't Fade
The roots of the current pessimism trace back to July, when the experimental drug Ziltivekimab failed to meet its study objectives. For a company whose future valuation depends heavily on the next generation of metabolic and obesity treatments, the miss was more than a clinical disappointment — it struck at the heart of Novo Nordisk's growth narrative.
The fallout was compounded in August when management trimmed its 2026 revenue outlook to a range of 0 to minus 6 percent. That revision, alongside the Ziltivekimab failure, prompted Deutsche Bank to downgrade the stock to "Sell" with a price target of DKK 265 at the end of August. The bank cited slower growth prospects for 2027, the shelved program, and the long-term threat of patent expirations. Even when the shares rallied in early September, Deutsche Bank reaffirmed its bearish stance.
JPMorgan takes a more measured view, maintaining a "Neutral" rating with a price target of DKK 275, while Citi aligns with Deutsche Bank's "Sell" recommendation and DKK 265 target. The analyst community's skepticism, in other words, is broad and persistent.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Competitive Squeeze Intensifies
Novo Nordisk's challenges are not confined to its own pipeline. Across the Atlantic, Eli Lilly continues to widen its moat. The US rival secured FDA approval for Mounjaro in late August to reduce cardiovascular risk and has completed several acquisitions in the vaccine and biotech space to diversify beyond metabolic therapies.
The market's preference is visible in institutional flows. Billionaire investors including Ken Griffin's Citadel and Stanley Druckenmiller's Duquesne have significantly increased their Eli Lilly positions — a vote of confidence that Novo Nordisk currently lacks.
Meanwhile, pricing pressure in Novo Nordisk's core US market shows no sign of easing. Ozempic and Wegovy now cost $350 per month in the United States, while insulin products have been reduced to $35. These concessions help defend market share but squeeze margins in the process.
Glimmers of Pipeline Progress
It would be inaccurate to suggest Novo Nordisk's research engine has stalled entirely. The company recently reported progress on an injectable obesity medication in a key Phase 3 trial and has advanced a new obesity candidate, NNC0721-8060, into first-in-human studies.
On the commercial front, the oral Wegovy tablet has begun its rollout in Germany, and a regulatory submission has been filed in China. These developments represent genuine catalysts, yet they have done little to dislodge the prevailing bearish thesis among analysts.
What London Must Deliver
All roads now lead to the September 21 Capital Markets Day, where management must present a coherent response to three converging pressures: the failed study, the lowered guidance, and Eli Lilly's accelerating momentum.
Investors will be looking for clarity on pipeline prioritization — specifically, whether the company can articulate a credible path forward for its obesity franchise beyond the current generation of products. The Deutsche Bank "Sell" call, with its emphasis on 2027 growth concerns and patent cliffs, frames the challenge starkly: Novo Nordisk needs to demonstrate that its next wave of innovation can arrive before the current one loses its protective moat.
The stock's technical position adds urgency. Trading 27% below its January peak and beneath its 50-day average, the shares have already priced in considerable disappointment. Whether the London event can reset that narrative — or merely confirm the bears' thesis — will likely determine the stock's trajectory into the final quarter of the year. For now, the market is withholding judgment, but patience has its limits.
Ad
Novo Nordisk Stock: New Analysis - 7 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
